Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205970 | 0.86 | ALDH1A1 (0.55) | ALDH1A1HPGDTDP1NPC1POLB | |
| SCHEMBL5831442 | 0.86 | ALDH1A1 (0.44) | ALDH1A1HPGDTDP1NPC1POLB | |
| SCHEMBL1545001 | 0.82 | POLB (0.47) | ALDH1A1HPGDTDP1NPC1POLB | |
| SCHEMBL10962786 | 0.81 | HPGD (0.50) | ALDH1A1HPGDNPC1RAB9AKMT2A | |
| SCHEMBL2894903 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDNPC1POLBRAB9A | |
| SCHEMBL28048975 | 0.81 | RXFP1 (0.46) | ALDH1A1HPGDNPC1POLBRAB9A | |
| SCHEMBL28048992 | 0.81 | CA1 (0.41) | ALDH1A1HPGDTDP1NPC1POLB | |
| SCHEMBL10807629 | 0.81 | HDAC1 (0.46) | ALDH1A1HPGDNPC1POLBRAB9A | |
| SCHEMBL2489381 | 0.81 | HDAC1 (0.42) | ALDH1A1HPGDNPC1POLBRAB9A | |
| SCHEMBL2897575 | 0.80 | LMNA (0.44) | ALDH1A1HPGDNPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | claimed |
| US-7381734-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2008-06-03 | — | — | US | claimed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | claimed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | claimed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | claimed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | claimed |
| US-20040116439-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2004-06-17 | — | — | US | claimed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | claimed |
| EP-1294691-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-03-26 | — | — | EP | claimed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | claimed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001096305-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | claimed |
| WO-1999011633-A1 | TRIAZINES WITH AN ADENOSINE ANTAGONISTIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-03-11 | — | — | WO | claimed |
| EP-0387201-B1 | Mixture of dyestuffs and their use | CIBA GEIGY AG (CH) | 1994-02-02 | — | — | EP | claimed |
| US-5131919-A | Trichromic dyeing or printing | CIBA-GEIGY CORPORATION (US) | 1992-07-21 | — | — | US | claimed |
| EP-0387201-A1 | Mixture of dyestuffs and their use | CIBA-GEIGY AG (CH) | 1990-09-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | ALDH1A1 1913/4885HPGD 313/4885TDP1 1067/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | ALDH1A1 1335/4885HPGD 1054/4885TDP1 1617/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | ALDH1A1 1903/4885HPGD 1263/4885TDP1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.